๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Gammora clinical trials

Also listed in trial records as 3TC, Dolutegravir (DTG) and lamivudine, Tenofovir disoproxil fumarate (TDF)/ lamivudine
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 6 trials in our China, Brazil and Spain registers that name Gammora as an intervention. Synced 26 Sep 2026
6Current trials
4Recruiting now
5Lead sponsors
3Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards
At a glance

Gammora is named as an intervention in 6 current clinical trials in our China, Brazil and Spain registers. 4 are recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Guangzhou 8th People's Hospital (2). The most-studied condition is HIV/AIDS.

Trials by status

  • Recruiting467%
  • Active, closed233%

Trials by phase

  • Observational350%
  • Phase 2/3117%
  • Phase 2117%
  • Phase 3117%
01

Clinical trials of Gammora

6 trials
StudyPhaseStatusLead sponsorRegisters
Dolutegravir/Lamivudine Dual Therapy for ART-naรฏve People With HIV and TB Receiving Rifampin-based TB Treatment
NCT06497465 · ClinicalTrials.gov ↗ · Tuberculosis, HIV
Phase 3 Recruiting Johns Hopkins University Brazil
Simplified Treatment of Anti-retrovirus in China (C-STAR)
NCT03603977 · ClinicalTrials.gov ↗ · HIV/AIDS
Observational Recruiting Guangzhou 8th People's Hospital China
Dolutegravir Plus Lamivudine Simplified Therapy
NCT03884673 · ClinicalTrials.gov ↗ · HIV/AIDS
Observational Recruiting Guangzhou 8th People's Hospital China
Good-first: B/F/TAF As First-line ART
NCT06619288 · ClinicalTrials.gov ↗ · HIV Infection
Observational Recruiting Affiliated Hospital of Nantong University China
DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old
NCT04337450 · ClinicalTrials.gov ↗ · HIV Infections
Phase 2/3 Active, closed PENTA Foundation Spain
Clinical Trial of Gammoraยฎ Plus Antiretroviral Treatment for HIV
NCT06799650 · ClinicalTrials.gov ↗ · HIV Seropositivity
Phase 2 Active, closed Federal University of Sรฃo Paulo Brazil

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Gammora

6 conditions
HIV/AIDS2HIV Infection1HIV Infections1HIV Seropositivity1Tuberculosis1HIV1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Guangzhou 8th People's Hospital2
Affiliated Hospital of Nantong University1
PENTA Foundation1
Federal University of Sรฃo Paulo1
Johns Hopkins University1
04

By country register

RegisterTrialsRecruiting
Clinical trials in China33
Clinical trials in Brazil21
Clinical trials in Spain10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Gammora trials

How many clinical trials are testing Gammora?

6 current trials in our China, Brazil and Spain registers name Gammora (also registered as 3TC) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Gammora trials recruiting patients?

Yes. 4 of the 6 trials are recruiting: 3 with sites in China and 1 with sites in Brazil. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Gammora clinical trials?

Guangzhou 8th People's Hospital (2), Affiliated Hospital of Nantong University (1), PENTA Foundation (1) and Federal University of Sรฃo Paulo (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Gammora works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Gammora works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gammora (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.